We can’t have a good life if we are more superficial and forgetful than Dementia Joe.
I just saw swarms of NPCs applauding some threatening messages from Elon Musk to Fauci and Bill Gates. And all I could think is that the collective mental is in a Joe Biden stage. Here’s why, if you need further explanations:
Elon Musk shares details about Tesla’s mRNA microfactories for CureVac
By CureVac, November 9, 2020
Elon Musk shared some details about Tesla’s mRNA microfactories for CureVac’s COVID vaccine development recently. In February 2019, CureVac published a press release that referred to a bioreactor dubbed The RNA Printer. Musk’s recent tweet provided some details about the bioreactor Tesla developed for CureVac’s mRNA vaccine initiatives.
“Tesla makes the RNA Bioreactor that can make vaccines/cures. Curevac has Version 2 in use. Version 3 is under development. I do expect this to become an important product for the world, but probably not financially for Tesla,” Musk stated on Twitter as a response to an inquiry from Tesla owner-investor @SamTalksTesla.
Musk discussed Tesla’s partnership with CureVac in July 2020 and shared his thoughts about the potential of synthetic RNA and DNA. At the time, Musk referred to diseases as a “software problem.” With that perspective, Tesla seems more than capable of developing technology to manufacture mRNA vaccines at scale. Musk visited CureVac’s headquarters in Tübingen, Germany in September to discuss Tesla subsidiary Grohmann Automation’s contribution to the development of CureVac’s mRNA COVID vaccine.
mRNA vaccines are easier to produce and scale compared to traditional ones. Tesla’s RNA Bioreactor will come into play during the production stage of CureVac’s COVID vaccine, once it is approved. Due to the scalability of mRNA vaccines, Tesla’s RNA Bioreactor might play a key role in making CureVac’s COVID vaccine easily accessible to the public.
Last week, CureVac reported positive results in Phase 1 of its COVID vaccine candidate. “We are very encouraged by the interim Phase 1 data. It represents a critical milestone in our COVID-19 vaccine program and strongly supports the advancement of our vaccine candidate,” said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
“Following further data readouts and discussion with regulatory authorities, we remain fully committed and on track to initiate a pivotal Phase 2b/3 trial before the end of 2020,” he added.
As of this writing, there have been no mRNA vaccines licensed for infectious disease because they are relatively new in the world of medicine. This new type of vaccine allows scientists to create synthetic mRNA, which contains the code for infectious proteins that create a virus’ molecules.
Vaccines that make synthetic mRNA cannot form a full virus, but it can develop enough of its parts to trigger the body’s immune system. The human body has innate immunity, which are defense systems we are born with, and acquired immunity, which develops over time as we come into contact with pathogens. Traditional vaccines work more with the acquired immune system, while mRNA vaccines have the potential to trigger the body’s innate immune system. Since it is incapable of developing full viruses, mRNA vaccine patients cannot spread the disease either.
Elon Musk visits CureVac in Germany, explores Tesla’s role in vaccine development
from: Teslarati, September 2, 2020
Elon Musk’s trip to Germany appears to have started on a high note, as the CEO experienced nothing short of a rockstar welcome during his visit to the headquarters of CureVac in Tübingen on Tuesday evening. Local reports indicate that the internal visit was aimed at discussing cooperation between the biotech company and Tesla subsidiary Grohmann Automation for the production of RNA mini-factories that could be used for the development of vaccines.
In a statement to SWR News, a CureVac spokesperson noted that the talks between Musk and the biotech company were held without any media present, as per the Tesla CEO’s request. CureVac is currently running a large-scale effort to develop a vaccine for the COVID-19 virus for the market in about two years. By then, the biotech company expects to have the capability to deliver billions of doses of vaccines for those in need.
Musk’s visit was highly-anticipated by Tesla fans in the area. Since Tuesday morning, a crowd of onlookers and photographers were already present at the CureVac site in Tübingen. Fans ended up waiting for hours for the CEO, at times even weathering some rain. Musk finally arrived in a black Model X at about 4:27 local time, followed by his entourage riding in another Tesla. Fortunately, at about 8:18 pm local time, Musk emerged from the facility, strolling between the CureVac headquarters and the Tübingen observatory.
Musk’s rockstar welcome was evident during his brief time with his fans. Surrounded by young Tesla enthusiasts, some of whom were holding signs indicating their intention to eventually work for the CEO, Musk seemingly interacted with some of his fans in a candid manner. Images from the event showed Musk, donning a bandanna in place of a face mask, walking with a group of about 30 people. Til Schwarze, one of those who waited for the CEO, later noted on Twitter that the long wait for Musk was well worth it.
Thank you @elonmusk for visiting #tübingen , waited so long to see you and it was worth it #elonmusk #tesla pic.twitter.com/1cBPOkhT73— Til Schwarze (@tilschwarze) September 1, 2020
Musk’s visit to Germany has several goals. In a post on Twitter, the CEO noted that conversations with Harvard epidemiology have indicated that the high-speed RNA printer technology has the potential to be helpful for the development of vaccines. Tesla and CureVac, incidentally enough, are currently developing and building RNA microfactories, which could greatly help in the ongoing fight against the pandemic. Back in July, Musk noted that with synthetic RNA and DNA, the solution to many diseases essentially becomes a “software problem.”
“In principle, I think synthetic RNA (and DNA) has amazing potential. This basically makes the solution to many diseases a software problem. Tesla, as a side project, is building RNA microfactories for CureVac & possibly others,” Musk wrote.
While Tesla and CureVac’s collaboration has been placed on the spotlight due to the pandemic, a joint patent application from 2018 reveals that the two companies have already been working on RNA-related innovations long before the initial COVID-19 outbreak. Descriptively titled “Bioreactor for RNA in vitro Transcription,” the patent outlined how Tesla’s mastery in automation could help expedite the manufacturing of RNA.
well, guess who finances curevac
Wikipedia goes on:
In October 2013, CureVac launched a collaboration with Janssen Pharmaceuticals Inc., a Johnson & Johnson company, for the development of novel flu vaccines.[15] Also in 2013, CureVac announced the fourth in a series of partnerships with the Cancer Research Institute and Ludwig Cancer Research to enable clinical testing of novel cancer immunotherapy treatment options.[16]
In March 2014, CureVac won a €2 million prize awarded by the European Commission to stimulate new vaccine technologies.[17] Later, in July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine.[18] By September 2014, the company licensed the global rights for its Phase I candidate – CV9202 – to Boehringer Ingelheim. Boehringer was to conduct trials using the mRNA vaccine in combination with afatinib in advanced and/or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as well as inoperable stage III NSCLC.[19]
In March 2015, a CureVac investor, the Bill & Melinda Gates Foundation, agreed to provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary mRNA platform.[20] By September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, utilizing immunogens developed by IAVI and partners, delivered via CureVac’s mRNA technology.[21] That same month, CureVac announced it would open a United States hub in Boston, Massachusetts.[22]
In accordance with its deal with Eli Lilly and Company, the company began construction on a production facility in 2016.[23]
In February 2019, the Coalition for Epidemic Preparedness Innovations (CEPI) awarded CureVac a $34 million grant to develop its proprietary “RNA printer” prototype.[24] The technology is expected to allow the company to rapidly produce mRNA vaccine candidates at scale from multiple locations globally to bypass the logistical hurdles that often delay the production of vaccines in response to infectious disease emergencies. It is also expected to enable the production of personalized medicines.[24] The initial uses would be for their candidate vaccines for Lassa fever, yellow fever, and rabies.[24]
In July 2020, Tesla, Inc CEO Elon Musk announced via a Tweet that Tesla and CureVac had reached an agreement to produce portable “RNA microfactories” based on this technology to manufacture CureVac’s COVID-19 vaccine candidate.[24] CureVac had stated that the bioprinters would be able to produce “more than a hundred thousand doses” within approximately two weeks.[24] At approximately the same time, Tesla and CureVac filed a joint patent on the technology.[25] In August, Musk reviewed the project with Curevac while in Germany.
Reports of Trump administration overtures
On 11 March 2020, it was reported that CureVac AG’s CEO Daniel Menichella was no longer the company’s CEO, having been replaced by the company founder Ingmar Hoerr. Menichella was reported to have met U.S. President Donald Trump on 2 March.[28][29] According to Welt am Sonntag, quoting an anonymous German government source, Trump had attempted to persuade CureVac to relocate to the United States, a proposal vigorously rejected by German officials.[30] On 16 March, CureVac issued a statement on Twitter, stating “To make it clear again on coronavirus: CureVac has not received from the US government or related entities an offer before, during and since the Task Force meeting in the White House on March 2. CureVac rejects all allegations from press.”
Speaking of Davos…
To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Click this link for the original source of this article.
Author: Silviu "Silview" Costinescu
This content is courtesy of, and owned and copyrighted by, https://silview.media and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
